About company
The Company, through its wholly owned subsidiaries Lyramid, Kinera, and Advangen, develops and markets innovative novel therapies and diagnostic tests for inflammatory and fibrotic diseases, cancer, ischemic diseases of the heart, and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally.
- AU 55 clarence street
- Unknown
- Unknown
- cellmid.com.au
- Not verified company
